ATE194981T1 - Oxazolidinderivat und sein pharmazeutisch verträgliches salz - Google Patents
Oxazolidinderivat und sein pharmazeutisch verträgliches salzInfo
- Publication number
- ATE194981T1 ATE194981T1 AT93911946T AT93911946T ATE194981T1 AT E194981 T1 ATE194981 T1 AT E194981T1 AT 93911946 T AT93911946 T AT 93911946T AT 93911946 T AT93911946 T AT 93911946T AT E194981 T1 ATE194981 T1 AT E194981T1
- Authority
- AT
- Austria
- Prior art keywords
- represent
- alkyl
- alkylene
- optionally halogenated
- pharmaceutically acceptable
- Prior art date
Links
- 150000002917 oxazolidines Chemical class 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000002947 alkylene group Chemical group 0.000 abstract 3
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- -1 2-oxazolyl Chemical group 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11177392 | 1992-04-30 | ||
| PCT/JP1993/000559 WO1993022298A1 (fr) | 1992-04-30 | 1993-04-28 | Derive d'oxazolidine et son sel pharmaceutiquement acceptable |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE194981T1 true ATE194981T1 (de) | 2000-08-15 |
Family
ID=14569807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT93911946T ATE194981T1 (de) | 1992-04-30 | 1993-04-28 | Oxazolidinderivat und sein pharmazeutisch verträgliches salz |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5480899A (de) |
| EP (1) | EP0605729B1 (de) |
| KR (1) | KR0146931B1 (de) |
| AT (1) | ATE194981T1 (de) |
| AU (1) | AU653896B2 (de) |
| CA (1) | CA2112129C (de) |
| DE (1) | DE69329106T2 (de) |
| FI (1) | FI935920L (de) |
| HU (2) | HU220601B1 (de) |
| WO (1) | WO1993022298A1 (de) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE194981T1 (de) * | 1992-04-30 | 2000-08-15 | Taiho Pharmaceutical Co Ltd | Oxazolidinderivat und sein pharmazeutisch verträgliches salz |
| PL186176B1 (pl) * | 1992-12-23 | 2003-11-28 | Bristol Myers Squibb Co | Sposób wytwarzania zawierającego oksazolinowy łańcuch boczny taksanu, zwierający łańcuch boczny taksan, oksazolinowy związek, sposób wytwarzania związku oksazolinowego, sposób wytwarzania zawierającego łańcuch boczny taksanu, pochodna taksanu, prekursor paklitakselu, sposób wytwarzania bakatyny, sposób wytwarzania paklitakselu i pochodna bakatyny |
| TW268952B (de) * | 1993-02-26 | 1996-01-21 | Takeda Pharm Industry Co Ltd | |
| DE4332384A1 (de) * | 1993-09-23 | 1995-03-30 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten III |
| TW286317B (de) * | 1993-12-13 | 1996-09-21 | Hoffmann La Roche | |
| DE4408534A1 (de) * | 1994-03-14 | 1995-09-28 | Hoechst Ag | Substituierte N-Ethyl-Glycinderivate zur Herstellung von PNA und PNA-/DNA-Hybriden |
| DE4425612A1 (de) * | 1994-07-20 | 1996-04-04 | Bayer Ag | 6-gliedrige stickstoffhaltige Heteroaryl-oxazolidinone |
| EP0710657B1 (de) | 1994-11-02 | 1998-08-26 | MERCK PATENT GmbH | Adhäsionsrezeptor-Antagonisten |
| US6465650B1 (en) | 1995-03-13 | 2002-10-15 | Aventis Pharma Deutschland Gmbh | Substituted N-ethylglycine derivatives for preparing PNA and PNA/DNA hybrids |
| PL345162A1 (en) | 1998-06-05 | 2001-12-03 | Astrazeneca Ab | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them |
| GB9812019D0 (en) * | 1998-06-05 | 1998-07-29 | Zeneca Ltd | Chemical compounds |
| GB9928568D0 (en) | 1999-12-03 | 2000-02-02 | Zeneca Ltd | Chemical compounds |
| GB0009803D0 (en) * | 2000-04-25 | 2000-06-07 | Astrazeneca Ab | Chemical compounds |
| EP1365745A2 (de) | 2001-02-15 | 2003-12-03 | King Pharmaceuticals, Inc. | Stabilisierte pharmazeutische und schilddrüsenhormon-zusammensetzungen und herstellungsverfahren |
| US7101569B2 (en) | 2001-08-14 | 2006-09-05 | Franz G Andrew | Methods of administering levothyroxine pharmaceutical compositions |
| DOP2005000123A (es) * | 2004-07-02 | 2011-07-15 | Merck Sharp & Dohme | Inhibidores de cetp |
| CA2635262C (en) * | 2005-12-30 | 2011-08-16 | Merck & Co., Inc. | 1, 3-oxazolidin-2-one derivatives useful as cetp inhibitors |
| US7910592B2 (en) | 2005-12-30 | 2011-03-22 | Merck Sharp & Dohme Corp. | CETP inhibitors |
| US8835426B2 (en) * | 2007-02-26 | 2014-09-16 | Vitae Pharmaceuticals, Inc. | Cyclic urea and carbamate inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
| WO2008120655A1 (ja) | 2007-03-30 | 2008-10-09 | Institute Of Medicinal Molecular Design, Inc. | Ｉ型１１βヒドロキシステロイド脱水素酵素阻害活性を有するオキサゾリジノン誘導体 |
| JP5451611B2 (ja) * | 2007-07-26 | 2014-03-26 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１のサイクリックインヒビター |
| AR069207A1 (es) * | 2007-11-07 | 2010-01-06 | Vitae Pharmaceuticals Inc | Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1 |
| JP5490014B2 (ja) | 2007-12-11 | 2014-05-14 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の環状尿素阻害剤 |
| TW200934490A (en) * | 2008-01-07 | 2009-08-16 | Vitae Pharmaceuticals Inc | Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1 |
| JP5490020B2 (ja) * | 2008-01-24 | 2014-05-14 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状カルバゼート及びセミカルバジドインヒビター |
| WO2009094265A1 (en) * | 2008-01-24 | 2009-07-30 | Merck & Co., Inc. | 3,5-substituted-1,3-oxazolidin-2-one derivatives |
| CA2714532A1 (en) * | 2008-02-11 | 2009-08-20 | Vitae Pharmaceuticals, Inc. | 1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1 |
| EP2254872A2 (de) * | 2008-02-15 | 2010-12-01 | Vitae Pharmaceuticals, Inc. | Cycloalkyllactamderivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1 |
| EP2274287B1 (de) * | 2008-03-18 | 2016-03-09 | Vitae Pharmaceuticals, Inc. | Inhibitoren der 11beta-hydroxysteroiddehydrogenase vom typ 1 |
| US8242111B2 (en) * | 2008-05-01 | 2012-08-14 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
| DK2300461T3 (da) * | 2008-05-01 | 2013-06-03 | Vitae Pharmaceuticals Inc | Cycliske inhibitorer af 11beta-hydroxysteroid-dehydrogenase 1 |
| CA2723039A1 (en) | 2008-05-01 | 2009-11-05 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| EP2291370B1 (de) | 2008-05-01 | 2013-11-27 | Vitae Pharmaceuticals, Inc. | Cyclische inhibitoren von 11beta-hydroxysteroiddehydrogenase 1 |
| TW201016691A (en) | 2008-07-25 | 2010-05-01 | Boehringer Ingelheim Int | Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| DK2324018T3 (da) | 2008-07-25 | 2013-10-14 | Boehringer Ingelheim Int | Cykliske inhibitorer af 11 beta-hydroxysteroid dehydrogenase 1 |
| IES20090901A2 (en) * | 2008-11-28 | 2010-07-07 | Corden Pharma Ip Ltd | Manufacture of beta blockers |
| US8637505B2 (en) | 2009-02-04 | 2014-01-28 | Boehringer Ingelheim International Gmbh | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| GEP20156309B (en) * | 2009-04-30 | 2015-07-10 | Vitae Pharmaceuticals Inc | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| UA109255C2 (ru) | 2009-04-30 | 2015-08-10 | Берінгер Інгельхайм Інтернешнл Гмбх | Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1 |
| WO2011011123A1 (en) | 2009-06-11 | 2011-01-27 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure |
| US8883778B2 (en) | 2009-07-01 | 2014-11-11 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1 |
| WO2011159760A1 (en) | 2010-06-16 | 2011-12-22 | Vitae Pharmaceuticals, Inc. | Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use |
| EP2585444B1 (de) | 2010-06-25 | 2014-10-22 | Boehringer Ingelheim International GmbH | Azaspirohexanone als 11-beta-hsd1-hemmer zur behandlung von stoffwechselerkrankungen |
| AU2011325286B2 (en) | 2010-11-02 | 2015-04-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations for the treatment of metabolic disorders |
| WO2017184072A1 (en) * | 2016-04-22 | 2017-10-26 | Kat2Biz Ab | Difunctional grafting agent based on phenolic backbone from lignin |
| EP3448859B1 (de) | 2017-03-20 | 2019-07-10 | Forma Therapeutics, Inc. | Pyrrolopyrrolzusammensetzungen als pyruvatkinase(pkr)-aktivatoren |
| EP3853206B1 (de) | 2018-09-19 | 2024-04-10 | Novo Nordisk Health Care AG | Behandlung von sichelzellanämie mit einer pyruvatkinase-r-aktivierenden verbindung |
| JP7450610B2 (ja) | 2018-09-19 | 2024-03-15 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | ピルビン酸キナーゼｒの活性化 |
| CN114615977B (zh) | 2019-09-19 | 2025-01-14 | 诺沃挪第克健康护理股份公司 | 丙酮酸激酶r(pkr)活化组合物 |
| WO2022075645A1 (ko) * | 2020-10-08 | 2022-04-14 | 재단법인 대구경북첨단의료산업진흥재단 | Pcsk9 억제제로서 아미노알콜 유도체 및 이를 함유하는 고콜레스테롤 혈증의 예방 또는 치료용 약학적 조성물 |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3020262A (en) * | 1957-12-19 | 1962-02-06 | Jefferson Chem Co Inc | Method for producing 2-oxazolidones from epoxides and isocyanates |
| DE3205457A1 (de) * | 1982-02-16 | 1983-08-25 | Merck Patent Gmbh, 6100 Darmstadt | Oxazolidin-2-one |
| US4602093A (en) * | 1984-02-08 | 1986-07-22 | Merck & Co., Inc. | Novel substituted imidazoles, their preparation and use |
| EP0394440B1 (de) * | 1987-10-20 | 1994-05-11 | Otsuka Pharmaceutical Co., Ltd. | Phenylcarbonsäure-abkömmlinge |
| CA1330079C (en) * | 1988-10-13 | 1994-06-07 | Michihiko Tsujitani | Pyrrolo (3,2-e)pyrazolo(1,5-a)pyrimidine derivative and medicine comprising the same |
| DK0393607T3 (da) * | 1989-04-19 | 1996-03-18 | Otsuka Pharma Co Ltd | Phenylcarboxylsyrederivater med en heteroring |
| ATE194981T1 (de) * | 1992-04-30 | 2000-08-15 | Taiho Pharmaceutical Co Ltd | Oxazolidinderivat und sein pharmazeutisch verträgliches salz |
-
1993
- 1993-04-28 AT AT93911946T patent/ATE194981T1/de not_active IP Right Cessation
- 1993-04-28 CA CA002112129A patent/CA2112129C/en not_active Expired - Fee Related
- 1993-04-28 EP EP93911946A patent/EP0605729B1/de not_active Expired - Lifetime
- 1993-04-28 WO PCT/JP1993/000559 patent/WO1993022298A1/ja active IP Right Grant
- 1993-04-28 KR KR1019930704109A patent/KR0146931B1/ko not_active Expired - Fee Related
- 1993-04-28 HU HU9303787A patent/HU220601B1/hu not_active IP Right Cessation
- 1993-04-28 US US08/167,798 patent/US5480899A/en not_active Expired - Fee Related
- 1993-04-28 AU AU42710/93A patent/AU653896B2/en not_active Ceased
- 1993-04-28 DE DE69329106T patent/DE69329106T2/de not_active Expired - Fee Related
- 1993-12-29 FI FI935920A patent/FI935920L/fi not_active IP Right Cessation
-
1995
- 1995-06-30 HU HU95P/P00726P patent/HU211901A9/hu unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU4271093A (en) | 1993-11-29 |
| EP0605729A4 (en) | 1994-08-24 |
| HU220601B1 (hu) | 2002-03-28 |
| HU211901A9 (en) | 1996-01-29 |
| CA2112129A1 (en) | 1993-11-11 |
| CA2112129C (en) | 1997-10-07 |
| AU653896B2 (en) | 1994-10-13 |
| DE69329106D1 (de) | 2000-08-31 |
| WO1993022298A1 (fr) | 1993-11-11 |
| DE69329106T2 (de) | 2001-03-22 |
| EP0605729B1 (de) | 2000-07-26 |
| HUT70423A (en) | 1995-10-30 |
| FI935920A0 (fi) | 1993-12-29 |
| US5480899A (en) | 1996-01-02 |
| KR0146931B1 (ko) | 1998-08-17 |
| FI935920L (fi) | 1993-12-29 |
| KR940701389A (ko) | 1994-05-28 |
| EP0605729A1 (de) | 1994-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE194981T1 (de) | Oxazolidinderivat und sein pharmazeutisch verträgliches salz | |
| FI932445A0 (fi) | Farmaceutiska foereningar | |
| MA20770A1 (fr) | Nouveaux acides quinolone-carboxyliques substitues a substituant diazabicycloalkyle ponte | |
| MX9200015A (es) | Derivados de amida y proceso para su preparacion. | |
| NZ238181A (en) | N-(1-substituted-piperidinyl(alkyl))carbamic acid, urea and carboxamide derivatives and homologues thereof; preparatory processes and pharmaceutical compositions | |
| EP0495776A4 (de) | Stabilisierte komplexe bestehend aus stickoxyd/primäre amine zur verwendung als kardiovaskuläre wirkstoffe. | |
| PT91602A (pt) | Processo para a preparacao de compostos espiro com accao antibacteriana e de composicoes farmaceuticas que os contem | |
| DE69423139D1 (de) | Amid-Derivate mit anti-hypercholesterolemischer Wirkung, deren Herstellung und deren Verwendungen als Heilmittel | |
| ATE146473T1 (de) | Pyrazolopyridinverbindungen und verfahren zu ihrer herstellung | |
| ATE194828T1 (de) | Entzündungshemmendes und analgetisches äusserliches pflaster-präparat | |
| DE69132167D1 (de) | Kondensierte benzoxa-ringverbindung, deren herstellung sowie diese enthaltendes arzneimittel | |
| TW206970B (de) | ||
| DK154589D0 (da) | Acylderivater | |
| PT90725A (pt) | Processo para a preparacao de novos compostos cefem | |
| HUT64318A (en) | Process for production benzodpyrane derivativs and pharmaceutical preparations containing these compounds as effective substance | |
| MX9200777A (es) | 4-[(2-benzotiazolil)metilamino]-alfa-[(3,4-difluorofenoxi)metil]-1-pip eridetanol. | |
| ATE171704T1 (de) | Optisch wirksame alkylendioxybenzolderivate und ihre verwendung als arzneimittel | |
| DE69017839D1 (de) | NMDA-blockierende Verbindungen, pharmazeutische Präparate, deren Herstellung und Verwendung. | |
| DE69123757D1 (de) | Epoxysuccinamidsäurederivat | |
| ATE172959T1 (de) | Acylphenylglycin-derivat und dieses als aktivbestandteil enthaltendes vorbeugungs -und heilmittel gegen durch erhöhte collagenaseaktivität verursachte krankheiten | |
| ES2037004T3 (es) | Metodo para producir un compuesto relacionado con el antibiotico tan-749. | |
| NO924758L (no) | Nye amidinoaftylfurankarboksylatderivater og syreaddisjonssalter derav | |
| SE9201188L (sv) | Ny användning | |
| DE69011174D1 (de) | Catecholaminester. | |
| KR890002142A (ko) | 8α-아실아미노- 에르고린 화합물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |